Fair pricing in drug repurposing

As the representative of not-for-profit healthcare payers in 28 countries, 18 of which in Europe, AIM is concerned about the evolution of recent drug prices and the risks they pose to the sustainability of solidarity-based healthcare systems. AIM has developed a model to set a Fair Price for new medicines that combines affordability and support to innovation. The model is based on objective parameters and takes into account the costs of bringing a drug to the market, the therapeutical value of the drug and allows reasonable profit for the pharmaceutical industry. The model offers an alternative starting point for price negotiations and calls for a comprehensive, open and transparent debate and a paradigm shift in the pricing of medicines. The price calculation is carried out by indication, which makes it particularly well suited to repurposed medicines. Since June 2021, AIM has made available a unique tool that allows to calculate the European fair price for each new drug, the European Fair Price Calculator, publicly accessible on its website.